See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
WWE
Social Media
Boxing
Natural Disasters
Music
World Cup
Soccer
Donald Trump
Cryptocurrency
Artificial Intelligence
Instagram
All Elite Wrestling
Published • loading... • Updated

Dosing started in Phase 1 study of novel SCD therapy CLY-124

Summary by Sickle Cell Disease News
The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for sickle cell disease.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Sickle Cell Disease NewsSickle Cell Disease News

Dosing started in Phase 1 study of novel SCD therapy CLY-124

The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for sickle cell disease.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sickle Cell Disease News broke the news in on Tuesday, July 8, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Volunteering icon

Volunteering

Maryland icon

Maryland

News
For You
SearchBlindspotLocal